Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Soon-Shiong Envisions Better, Ultimately Cheaper Cancer Care

This article was originally published in Scrip

Executive Summary

Describing biotech billionaire Patrick Soon-Shiong as a big thinker is an understatement given the goals that he and his web of businesses have for improving the way cancer patients are treated, and now he's enlisting the help of other biopharma companies to test immunotherapy hypotheses.

You may also be interested in...



Finance Watch: Amylyx, CinCor And Vigil Ready The First Biopharma IPOs Of 2022

Public Company Edition: Mergers with special purpose acquisition corporations also continue to take companies public, with three new SPAC offerings in late 2021. Also, Xeris raised $30m in a private placement of stock to support its recently approved drug and Sirnaomics went public in Hong Kong.

Finance Watch: Up, Up And Away – Biopharma Stocks Keep Rising

Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs. 

IPO Update: Haircuts Needed To Price Biotech Offerings

The two drug developers that managed to launch initial public offerings in the US during the past two weeks had to accept rough haircuts in order to get investors to buy their newly issued stock.

Topics

UsernamePublicRestriction

Register

SC064597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel